Search Results

1 - 6 of 6 items :

  • pharmacokinetics x
  • Pediatrics and Juvenile Medicine x
  • Life Sciences x
  • Clinical Medicine x
  • Human Biology x
Clear All
Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych

Robak T Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly Expert Opin Drug Metab Toxicol 2015 11 1371 91 [11] Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59. 21094089 10.1016/S1470-2045(10)70261-8 Wilson WH O’Connor OA Czuczman MS et al Navitoclax, a targeted high

Open access
Retrospection of the effect of hydroxyurea treatment in patients with sickle cell disease

pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [ 16 ]. Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [ 76 ]. However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [ 58 ]. Studies in animal models revealed that that HU therapy inhibits spermatogenesis

Open access
Zastosowanie infuzyjnego schematu chemioterapii DA-EPOCH w leczeniu chłoniaków agresywnych

] schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas. A prospective multi-institutional study of administration of etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone (EPOCH therapy. Schemat chemioterapii EPOCH z podaniem leków w dawkach dostosowywanych, z lub bez dodatku rituximabu (DA-EPOCH(-R), dose adjusted -EPOCH - rituximab) jest leczeniem wykorzystującym długotrwałą infuzję cytostatyków, z modyfikacją dawek w kolejnych cyklach na podstawie obserwowanych parametrow

Open access
Implantoprosthetic rehabilitation of a patient with severe form of hemophilia B: a case report

subcommittee of factor VIII and factor IX of the scientific and standarization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost. 2001 85 560 [4] Lehmann-Kopydlowska M, Zawilska K. Dental guidelines in congenital hemophilia A and B. Czas Stomatol. 2010;63(6):345-357. Lehmann-Kopydlowska M Zawilska K. Dental guidelines in congenital hemophilia A and B Czas Stomatol. 2010 63 6 345 357 [5] Bjorkman S, Carlsson M, Berntop E. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation

Open access
Progressive arthropathy in the course of immune tolerance induction failure in a child with hemophilia A and FVIII inhibitor – a case report

with hemophilia A with inhibitors: results from the HAVEN 2 study Blood 2018 132 suppl 1 632 (abstr) [13] Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019. Published online April 16, 2019. Pipe SW Shima M Lehle M et al Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre

Open access
Stosowanie leków biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów

Kanakasetty GB et al Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study Lancet Haematol 2017 4 e350 61 [8] Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4:e362

Open access